From Symptoms to Stability: Emerging OX40/OX40L‐Targeted Therapies, Durable AD Control, and Enhanced Quality of Life

And we're gonna start out by talking about a novel therapeutic target.

Why would we target the OX40-OX40 ligand pathway to treat moderate to severe atopic dermatitis? And when we think about it, atopic dermatitis, especially for those patients who have moderate to severe disease, it consumes their lives.

They have itch, they have pain, they're not sleeping at night.

When they look at their skin, their skin doesn't look normal.

It's weepy.

It's oozy.

Sometimes it's bleeding.

It's red.

And all these factors go into effect.

Not only their mental health, we have a higher risk of anxiety and depression.

These people are stressed.

They feel isolated.

They don't want to communicate and get to know others.

Some people don't even want to leave the house when their skin is flaring.

You have to worry about your clothing.

You maybe don't want to wear something white because you might bleed through it.

It affects social life.

It affects your work life.

Patients are absent from work.

And when they're at work, they're not giving it their best.

So we definitely see a reduced productivity.

Now, when we think about the landscape and the therapeutic options for atopic dermatitis, it all starts with appropriate skincare.

And then for our patients with mild disease, we generally turn to topical therapy.

Topical corticosteroids have been the mainstay of therapy, but we have some new non-steroidal options that actually are quite helpful.

in getting these patients under control and simplifying the treatment regimen.